Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Foghorn Therapeutics stock

Own Foghorn Therapeutics stock in just a few minutes.

Foghorn Therapeutics Inc is a biotechnology business based in the US. Foghorn Therapeutics shares (FHTX) are listed on the NASDAQ and all prices are listed in US Dollars. Foghorn Therapeutics employs 95 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Foghorn Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – FHTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Foghorn Therapeutics share price

Use our graph to track the performance of FHTX stocks over time.

Foghorn Therapeutics shares at a glance

Information last updated 2021-04-29.
52-week range$9.85 - $28.27
50-day moving average $12.56
200-day moving average $16.75
Wall St. target price$25.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Foghorn Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Foghorn Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Foghorn Therapeutics financials

Revenue TTM $430,000
Gross profit TTM $-57,285,000
Return on assets TTM -30.82%
Return on equity TTM -95.05%
Profit margin 0%
Book value N/A
Market capitalisation $391 million

TTM: trailing 12 months

Shorting Foghorn Therapeutics shares

There are currently 737,264 Foghorn Therapeutics shares held short by investors – that's known as Foghorn Therapeutics's "short interest". This figure is 0.6% down from 741,814 last month.

There are a few different ways that this level of interest in shorting Foghorn Therapeutics shares can be evaluated.

Foghorn Therapeutics's "short interest ratio" (SIR)

Foghorn Therapeutics's "short interest ratio" (SIR) is the quantity of Foghorn Therapeutics shares currently shorted divided by the average quantity of Foghorn Therapeutics shares traded daily (recently around 120467.97385621). Foghorn Therapeutics's SIR currently stands at 6.12. In other words for every 100,000 Foghorn Therapeutics shares traded daily on the market, roughly 6120 shares are currently held short.

To gain some more context, you can compare Foghorn Therapeutics's short interest ratio against those of similar companies.

However Foghorn Therapeutics's short interest can also be evaluated against the total number of Foghorn Therapeutics shares, or, against the total number of tradable Foghorn Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Foghorn Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Foghorn Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0377% of the tradable shares (for every 100,000 tradable Foghorn Therapeutics shares, roughly 38 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Foghorn Therapeutics.

Find out more about how you can short Foghorn Therapeutics stock.

Foghorn Therapeutics share dividends

We're not expecting Foghorn Therapeutics to pay a dividend over the next 12 months.

Foghorn Therapeutics overview

Foghorn Therapeutics Inc. , a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. Foghorn Therapeutics Inc. has a research collaboration and license agreement with Merck Sharp & Dohme Corp.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site